Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

[1] Lazarou J(1998)Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA. 279 1200-1205

[2] Pomeranz BH(2017)HLA-associated drug hypersensitivity and the prediction of adverse drug reactions Pharmacogenomics. 18 1441-1457

[3] Corey PN(2001)Drug-related morbidity and mortality: updating the cost-of-illness model J Am Pharm Assoc (Wash) 41 192-199

[4] Negrini S(2004)Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol Sci 25 193-200

[5] Becquemont L(2012)Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther 92 414-417

[6] Ernst FR(2000)Graf von der Schulenburg JM. The influence of economic evaluation studies on decision making. A European survey. The EUROMET group Health Policy 52 179-192

[7] Grizzle AJ(2002)Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities Value Health 5 71-78

[8] Ingelman-Sundberg M(2008)Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects Int J Technol Assess Health Care 24 294-302

[9] Whirl-Carrillo M(2016)A systematic review of economic evaluations of Pharmacogenetic testing for prevention of adverse drug reactions Pharmacoeconomics. 34 771-793

[10] McDonagh EM(2005)Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997 J Health Serv Res Policy 10 245-250

[1] Lazarou J(1998)Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA. 279 1200-1205

[2] Pomeranz BH(2017)HLA-associated drug hypersensitivity and the prediction of adverse drug reactions Pharmacogenomics. 18 1441-1457

[3] Corey PN(2001)Drug-related morbidity and mortality: updating the cost-of-illness model J Am Pharm Assoc (Wash) 41 192-199

[4] Negrini S(2004)Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future Trends Pharmacol Sci 25 193-200

[5] Becquemont L(2012)Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther 92 414-417

[6] Ernst FR(2000)Graf von der Schulenburg JM. The influence of economic evaluation studies on decision making. A European survey. The EUROMET group Health Policy 52 179-192

[7] Grizzle AJ(2002)Do health-care decision makers find economic evaluations useful? The findings of focus group research in UK health authorities Value Health 5 71-78

[8] Ingelman-Sundberg M(2008)Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects Int J Technol Assess Health Care 24 294-302

[9] Whirl-Carrillo M(2016)A systematic review of economic evaluations of Pharmacogenetic testing for prevention of adverse drug reactions Pharmacoeconomics. 34 771-793

[10] McDonagh EM(2005)Use of evidence in decision models: an appraisal of health technology assessments in the UK since 1997 J Health Serv Res Policy 10 245-250